Incyte Ends Jakafi Pancreatic Cancer Trials, But Has More Irons In The Fire
This article was originally published in The Pink Sheet Daily
Executive Summary
Pancreatic trial failure means the end of the inflammation hypothesis for Jakafi and thus the end of related solid tumor trials, but trials of JAK inhibitors in other solid tumors still have potential, says Incyte.